Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) provides this centralized hub for investors and industry professionals tracking developments in life sciences innovation. Access official press releases, financial disclosures, and strategic updates from the global leader in bioactive reagents and diagnostic solutions.
This resource delivers timely updates on earnings results, product launches, and strategic collaborations critical to understanding the company's position in biotechnology markets. Users will find announcements related to protein analysis advancements, spatial biology innovations, and global distribution partnerships.
All content is sourced directly from Bio-Techne's corporate communications, ensuring accuracy for those monitoring investment opportunities or industry trends. Bookmark this page for efficient access to material developments affecting TECH's market performance and scientific impact.
ScaleReady has awarded a $200,000 G-Rex® Grant to March Biosciences to advance the manufacturing of MB-105, a novel CAR-T cell therapy. The therapy targets CD5 for patients with T-cell lymphomas and received FDA orphan drug designation in January 2025.
MB-105 is being developed for multiple CD5-positive blood cancers, including T-cell lymphoma, T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma. The therapy's proprietary design allows it to target malignant cells while preserving normal T-cell function.
The G-Rex Grant Program, which has awarded nearly 200 grants with over 50 new applications pending, provides up to $300,000 per recipient. Grant recipients gain access to ScaleReady's consortium of partners, offering expertise in:
- cGMP manufacturing
- Quality and regulatory affairs
- CGT business operations
The program has been extended with millions in additional funding to continue supporting cell and gene therapy development.
Bio-Techne (NASDAQ: TECH) has announced an Early Access Program for a new spatial protein proximity detection assay, built on RNAscope™ technology. The next-generation assay enables high-resolution visualization of protein interactions within intact tissues, providing functional insights into disease processes.
The technology addresses limitations of conventional methods by offering clear visual signals at subcellular resolution, compatible with the RNAscope™ Multiomic LS workflow on BOND RX. This advancement is particularly valuable for research in immune checkpoint dynamics, bispecific antibodies, and synaptic junction protein interactions.
The Early Access Program will be available to select institutions and researchers, with proof-of-concept data and case studies to be presented at the 2025 American Association for Cancer Research (AACR) annual meeting.
Bio-Techne (NASDAQ: TECH) has announced its participation in the 2025 American Association for Cancer Research (AACR) Annual Meeting from April 25-30 in Chicago. The company will showcase its oncology research portfolio at two booths:
At booth #3049, Bio-Techne will display its comprehensive portfolio including proteins, antibodies, cell culture reagents, and spatial multiomic solutions. Advanced Cell Diagnostics (ACD) will feature its RNAscope™ spatial portfolio and host an evening reception on April 27th.
At booth #3249, Lunaphore will present its spatial biology solutions, including a new fully-automated, same-section multiomics application for fixed-frozen tissue. The company will host a dinner reception on April 28th to showcase its HORIZON™ image analysis software.
The company will also present multiple scientific posters covering topics such as protein quantitation, biomarker evaluation, and spatial multiomics analysis in cancer research.
OmniAb (NASDAQ: OABI) has announced two strategic appointments to its Board of Directors: Philip J. Gotwals, Ph.D., and Steve Crouse, while Director Sarah Boyce steps down after nearly six years of service. These changes increase the board size to seven members.
Dr. Gotwals brings 30 years of biopharmaceutical experience, notably as Global Head of Business Development and Licensing at Novartis Institutes for BioMedical Research, where his team executed over 50 major strategic transactions. He will serve on the Human Capital Management & Compensation Committee and Science & Technology Committee.
Steve Crouse, currently Senior Vice President and General Manager of Bio-Techne's Analytical Solutions Division, contributes over 20 years of life sciences expertise. He will serve on the Audit Committee and Science & Technology Committee.
Bio-Techne (NASDAQ: TECH) has announced its upcoming third quarter fiscal 2025 financial results conference call and webcast, scheduled for Wednesday, May 7, 2025, at 8:00 a.m. CDT. Investors can access the live discussion through phone dial-in (1-877-407-9208 for domestic, 1-201-493-6784 for international callers) using Conference ID 13753150 or via webcast on the company's investor relations website.
For those unable to attend the live call, a recorded rebroadcast will be available from 11:00 a.m. CDT on May 7 until 11:00 p.m. CDT on June 7, 2025, accessible by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international).
Bio-Techne (NASDAQ: TECH) has expanded its partnership with Leica Biosystems to enhance spatial multiomics research capabilities. The collaboration focuses on automating Bio-Techne's new RNAscope™ Multiomic LS Assay on Leica's BOND RX research staining instrument.
The assay enables simultaneous detection of up to six RNA and/or protein biomarkers on a single slide while preserving sample integrity. Additionally, they introduced a protease-free workflow for RNAscope™ 2.5 single-plex assays. The RNAscope™ technology has been widely adopted globally, contributing to over 12,000 peer-reviewed publications.
This expansion builds upon their partnership established in 2015, focusing on automated in-situ hybridization workflows for spatial biology research.
Bio-Techne (NASDAQ: TECH) has announced plans to open a new Customer Experience Centre in Düsseldorf, Germany by summer 2026, aimed at serving the EMEA (Europe, Middle East and Africa) region. The facility will feature a state-of-the-art Demonstration Laboratory showcasing the company's complete instrument portfolio.
Key highlights include the newly launched Leo™ System with Simple Western™ Technology for automated western blot assays, and the COMET™ spatial biology platform for automated, high-throughput tissue profiling. The center will complement Bio-Techne's existing UK facility, allowing for expanded customer demonstrations and hands-on experience with their instruments.
The strategic location in Düsseldorf was selected for its vibrant life sciences sector and proximity to the Benelux region, facilitating access to multiple European markets. This expansion will enable Bio-Techne to grow its customer-facing team in EMEA and support long-term regional growth, particularly in the German market.
Bio-Techne (NASDAQ: TECH) announced advancements in its RNAscope technology for biomarker detection and pathology laboratory workflow improvements, to be presented at the 2025 USCAP Annual Meeting in Boston (March 22-27). The company's Advanced Cell Diagnostics brand will showcase the technology at booth #222.
During the 'RNAscope: Lightning Lunch and Learn' session on March 25, four leading pathologists will present their research:
- Dr. Rohit Mehra on TRIM63 mRNA as a marker in renal cell carcinoma
- Dr. Vikram Deshpande on albumin mRNA for liver tumors
- Dr. Brooke Howitt on point mutation detection in gynecologic tumors
- Dr. Gregory Bean on mRNA detection from CRTC1/3::MAML2 translocations
The presentations will demonstrate RNAscope's potential to improve performance over existing methods and reduce time to results in detecting clinically relevant biomarkers, including secreted proteins, point mutations, and chromosomal translocations.
Bio-Techne (NASDAQ: TECH) has launched Leo™, a next-generation Simple Western™ system that significantly enhances protein analysis capabilities. The system can process up to 100 samples in a single 3-hour run, delivering 4x higher throughput than the Jess™ system and 5x faster processing than Sally Sue™ and Peggy Sue™ systems.
Leo features enhanced Compass Software with advanced analysis capabilities and improved 21 CFR Part 11 Compliance support. The system offers experimental size, precision, and reproducibility suitable for regulatory submissions. Beta testers have praised Leo's robust performance and versatility across applications including targeted protein degradation, clinical biomarker studies, gene therapy potency assays, quality control, and recombinant protein expression.
Bio-Techne (NASDAQ: TECH) has announced the launch of the AmplideX® Nanopore Carrier Plus Kit, a genetic panel and analysis software for carrier screening research, developed in collaboration with Oxford Nanopore Technologies. The innovative kit addresses challenges in analyzing genes that are difficult to assess using conventional short-read sequencing.
The 11-gene panel includes the most prevalent recommended genes that conventional methods struggle to detect accurately. By combining AmplideX long-range PCR and nanopore long reads, the kit provides a streamlined, single-workflow solution for comprehensive sequencing data, replacing the need for multiple testing technologies like MLPA, Sanger sequencing, qPCR, and long-range PCR.
The panel targets key genes including CFTR, CYP21A2, F8 inversions, FMR1, GBA, HBA1, HBA2, HBB, SMN1, SMN2, and TNXB. This development aligns with the American College of Medical Genetics and Genomics' 2021 updated recommendations for carrier screening.
FAQ
What is the current stock price of Bio-Techne (TECH)?
What is the market cap of Bio-Techne (TECH)?
